
Atopic Dermatitis and What Familiarity Can Miss
At Fall Clinical 2026, familiar presentations of atopic dermatitis invite another look at diagnosis, burden, and the point when the usual approach stops being enough.
By Dermsquared Editorial Team | October 06, 2026
Atopic dermatitis (AD) is one of dermatology’s most familiar diseases. That familiarity is useful right up until the patient in front of us stops behaving the way we expect.
Maybe the morphology is wrong or the distribution raises another possibility. The patient has already spent months eliminating triggers, changing products, and treating what seemed like the obvious culprit. Or perhaps the diagnosis itself is no longer the difficult part. The skin is recognizably AD; what is harder to name is the moment when a treatment plan that once made sense has stopped doing enough.
Both problems surface at Fall Clinical 2026, where the conversation around AD extends beyond the availability of effective systemic options to the decisions that come before them: recognizing disease accurately, understanding what it is actually costing the patient, and knowing when the current strategy deserves another look. The meeting’s AD programming includes discussion of treatment escalation, individualized biologic selection, and the role of patient-reported burden alongside visible disease.
Beyond the First Explanation
In a Fall Clinical case discussion, Mona Shahriari, MD, and E. James Song, MD, will revisit a patient whose chronic hand and foot disease initially suggested several reasonable possibilities.
The hyperkeratotic morphology had pointed toward psoriasis. Frequent exposure to water, food products, and other irritants made irritant contact dermatitis plausible; patch testing also identified relevant contact allergens. KOH testing, biopsy, expanded patch testing, allergen avoidance, and changes in hand care all became part of the diagnostic work. Still, significant disease persisted. Over time, the clinical course and diagnostic findings supported adult-onset AD involving the hands and feet.
There is no tidy diagnostic trick hidden in that progression. The earlier possibilities were not unreasonable; they simply failed to account for the whole course of disease. Phenotype is only one part of assessment in AD. A contemporary evaluation can also include symptom severity, disease evolution, comorbidities, prior response to therapy, and the burden described by the patient rather than inferred from the examination alone.
Some patients make that discrepancy difficult to miss. Hands and feet may represent a relatively limited body surface area and still interfere with work, sleep, walking, cooking, caregiving, or nearly every repetitive task in a day. Elsewhere, the skin may look improved enough to reassure the clinician while itch, sleep disruption, or the effort required to maintain that improvement tells another story.
The question is rarely whether any treatment is working. More often, it is whether it is working enough.
Reconsidering the Threshold
Treatment escalation sounds clean in an algorithm. In the room, it tends to arrive less neatly. Topicals may help, but require a level of adherence the patient cannot sustain. Flares improve, then return. A patient learns to live around the disease, sometimes so gradually that both patient and clinician begin to describe a substantial burden as baseline.
Current AD guidance reflects a broader view of that decision. Severity assessment includes signs, symptoms, comorbidities, and the negative impact on quality of life; long-term management also asks clinicians to consider satisfaction with treatment and the ability to adhere to a regimen that maintains control. When optimized topical therapy remains inadequate, systemic treatment becomes part of the conversation.
Yet having more treatment options does not automatically tell us when to use them.
That may be one of the more useful conversations to carry out of Fall Clinical this year. As the therapeutic landscape has expanded, have our expectations for control moved with it? Are there patients still spending too long in regimens that produce intermittent improvement without changing the larger course of their disease? And when the skin looks somewhat better but the patient is still organizing life around AD, what exactly are we calling controlled?
Over the coming months, this experience will continue that discussion with Drs Shahriari, Song, and other faculty, moving from the cases and data presented at Fall Clinical into the decisions they inform in practice.
The challenge in AD is no longer simply recognizing what the disease can look like. Increasingly, it is recognizing when what we have accepted as familiar deserves to be reconsidered.